Correlation between antenatal magnesium sulfate (MgSO4) total dose and delivery time interval with umbilical cord blood brain-derived neurotrophic factor (BDNF) levels as a neuroprotection strategy in preterm birth

Muhammad Adrianes Bachnas; Sri Sulistyowati; Uchti Akbar

doi:10.15562/bmj.v11i1.2788

Correlation between antenatal magnesium sulfate (MgSO4) total dose and delivery time interval with umbilical cord blood brain-derived neurotrophic factor (BDNF) levels as a neuroprotection strategy in preterm birth

Muhammad Adrianes Bachnas ,

Sri Sulistyowati ,

Uchti Akbar ,

pdf |
DOI: https://doi.org/10.15562/bmj.v11i1.2788 |
Published: 2022-04-18

Abstract

Background: Administration of antenatal magnesium sulfate (MgSO₄) to pregnant women is thought to increase the synthesis of Brain-Derived Neurotrophic Factor (BDNF), which functions as a nerve-growth factor for the process of neurogenesis and also strengthen neuronal resilience in the hypoxic condition that occurs during preterm delivery. Protocols for administering antenatal MgSO4 differ between countries and institutions. One of the concerns is whether the dose is given and the time interval to delivery has a big contribution towards a better fetal outcome. These relationships have not been studied before. This study aimed to analyze the correlation of the total dose of MgSO4 and time interval to delivery with BDNF levels in cord blood.

Methods: This study enrolled 72 pregnant women who will deliver the baby prematurely, with gestational age 28-34 weeks. Subjects were divided into three protocols groups: (1) 4 g iv. only, (2) 4 g iv. initial continued with 1 g/hours until maximum 24 hours, and (3) 6 g iv. initial continued with 2 g/hours until a maximum of 24 hours. At the time of delivery, cord blood of preterm babies was collected. The antenatal MgSO4 total dose and time interval to delivery were collected, and BDNF serum levels were then measured with enzyme-linked immunosorbent assay (ELISA). The correlation between antenatal MgSO4 total dose and time interval to delivery with BDNF levels was analyzed using Spearman’s correlation test.

Result: There was a weak significant correlation of antenatal MgSO4 total dose and BDNF cord blood levels (p<0.001; r=0.381). There was no significant correlation between delivery time interval and BDNF cord blood levels (p=0.44; r=0.092).

Conclusion: Regarding the weak correlation of total dose and time interval to delivery with BDNF, we suggest that all protocols provide comparable outcomes if seen only from the BDNF increase perspective.

References

World Health Organization. Preterm birth. WHO Key Facts Preterm Birth. 2018.
Berliana SM, Sulistiarini D. Faktor-faktor yang memengaruhi kelahiran prematur di Indonesia: Analisis data riskesdas 2013. 2016;1(2):109–15.
Berger R, Söder S. Neuroprotection in preterm infants. Biomed Res Int. 2015;2015.
Peebles D, Kenyon AP. Magnesium sulphate to prevent cerebral palsy following preterm birth. RCOG Sci Impact Pap [Internet]. 2014 [cited 2019 Feb 9];29:7. Available from: https://www.rcog.org.uk/globalassets/documents/guidelines/scientific-impact-papers/sip_29.pdf
Brookfield KF, Elkomy M, Su F, Drover DR, Carvalho B. Optimization of maternal magnesium sulfate administration for fetal neuroprotection: Application of a prospectively constructed pharmacokinetic model to the BEAM cohort. J Clin Pharmacol [Internet]. 2017 Nov [cited 2019 Feb 9];57(11):1419–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28589614
Magee L, Sawchuck D, Synnes A, von Dadelszen P, Basso M, Crane JM, et al. Magnesium sulphate for fetal neuroprotection. J Obstet Gynaecol Canada [Internet]. 2011 May [cited 2019 Feb 9];33(5):516–29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21639972
Bachnas MA, Akbar MIA, Dachlan EG, Dekker G. The role of magnesium sulfate (MgSO 4) in fetal neuroprotection . J Matern Neonatal Med [Internet]. 2019;0(0):1–13. Available from: https://doi.org/10.1080/14767058.2019.1619688
Bachnas MA, Mose JC, Effendi JS, Andonotopo W. Influence of antenatal magnesium sulfate application on cord blood levels of brain-derived neurotrophic factor in premature infants. J Perinat Med [Internet]. 2014 Jan 1 [cited 2019 Feb 9];42(1):129–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19605775
Johnston M V, Trescher WH, Ishida A, Nakajima W, Zipursky A. The developing nervous system: A series of review articles: neurobiology of hypoxic-ischemic injury in the developing brain. Pediatr Res. 2001;49(6).
Husson I, Rangon CM, Lelièvre V, Bemelmans AP, Sachs P, Mallet J, et al. BDNF-induced white matter neuroprotection and stage-dependent neuronal survival following a neonatal excitotoxic challenge. Cereb Cortex. 2005;15(3).
Zeng X, Xue Y, Tian Q, Sun R, An R. Effects and safety of magnesium sulfate on neuroprotection. Medicine (Baltimore) [Internet]. 2016 Jan [cited 2019 Feb 9];95(1):e2451. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26735551
American College of Obstetricians and Gynecologists. Magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet Gynecol. 2010;115(455):669–71.
Okusanya BO, Oladapo OT, Long Q, Lumbiganon P, Carroli G, Qureshi Z, et al. Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia. BJOG An Int J Obstet Gynaecol. 2016;123(3):356–66.
Simchen MJ. Magnesium sulfate for fetal neuroprotection: Correlation between maternal and infant serum magnesium concentrations. Acad J Pediatr Neonatol. 2016;1(2):1–5.
Rao R, Mashburn CB, Mao J, Wadhwa N, Smith GM, Desai NS. Brain-derived neurotrophic factor in infants <32 weeks gestational age: Correlation with antenatal factors and postnatal outcomes. Pediatr Res. 2009;65(5):548–52.